title: Transient silencing of synaptic transmitter release from specific neuronal types by recombinant tetanus toxin light chain fused to antibody variable region.
abstract: We developed a novel strategy for conditional silencing of synaptic transmission in specific neuronal types in transgenic animals. We generated a recombinant protein termed immuno-tetanus toxin (ITet), which contains a monoclonal antibody variable region for human interleukin-2 receptor alpha-subunit (IL-2Ralpha) fused to tetanus toxin light chain. ITet was designed to transiently suppress transmitter release from target neurons genetically engineered to express human IL-2Ralpha via proteolytic cleavage of vesicle-associated membrane protein-2 (VAMP-2). The in vivo actions of ITet were investigated by using mutant mice that express IL-2Ralpha in striatal neurons under the control of the gene encoding dopamine D(2) receptor. Unilateral ITet injection into the striatum induced rotational behavior in the mutant mice and the rotations gradually reversed to the normal level. The behavioral alteration was accompanied by a transient decrease in the striatal VAMP-2 level and depolarization-evoked transmitter release in synaptic target region. However, ITet injection caused no structural change in striatal cells and nerve terminals in the mutants. These data indicate that ITet acts on striatal neurons bearing human IL-2Ralpha and temporally reduces their VAMP-2 content, thereby causing the blockade of transmitter release. Our ITet technology provides a useful approach for inducible and reversible control of synaptic transmission in specific neuronal types in the brain.
authors.affiliation: Department of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kai
authors.forename: Kenta
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Tomonori
authors.initials: T
authors.lastname: Fujiwara
authors.forename: Kimio
authors.initials: K
authors.lastname: Akagawa
authors.forename: Masanori
authors.initials: M
authors.lastname: Onda
authors.forename: Kazuto
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003342:Corpus Striatum / Q000166:cytology; D007839:Functional Laterality; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009474:Neurons / Q000187:drug effects*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D011189:Potassium Chloride / Q000494:pharmacology; D017448:Receptors, Dopamine D2 / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000494:pharmacology; D013744:Tetanus Toxin / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors; D050988:Vesicle-Associated Membrane Protein 2 / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D000906:Antibodies; D053645:Interleukin-2 Receptor alpha Subunit; D018377:Neurotransmitter Agents; D017448:Receptors, Dopamine D2; D011993:Recombinant Fusion Proteins; D013744:Tetanus Toxin; D050988:Vesicle-Associated Membrane Protein 2; D005680:gamma-Aminobutyric Acid; D011189:Potassium Chloride
references.citation: Trends Neurosci. 1990 Jul;13(7):281-5
references.pmid: 1695404
references.citation: Blood. 1994 Jan 15;83(2):426-34
references.pmid: 8286741
references.citation: J Biol Chem. 1990 Sep 5;265(25):15198-202
references.pmid: 2118522
references.citation: J Immunol. 2006 Dec 15;177(12):8822-34
references.pmid: 17142785
references.citation: J Neurosci. 2003 Oct 8;23(27):9078-88
references.pmid: 14534241
references.citation: Neurosci Res. 2007 Jun;58(2):118-23
references.pmid: 17313983
references.citation: Trends Neurosci. 2005 Jan;28(1):44-50
references.pmid: 15626496
references.citation: Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1132-6
references.pmid: 7862648
references.citation: J Neurosci. 2003 Jul 30;23(17):6759-67
references.pmid: 12890769
references.citation: Science. 2000 Jul 28;289(5479):633-7
references.pmid: 10915629
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13940-5
references.pmid: 14615590
references.citation: Neuron. 2006 Jul 20;51(2):157-70
references.pmid: 16846851
references.citation: Neuron. 2005 Dec 8;48(5):727-35
references.pmid: 16337911
references.citation: Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1352-7
references.pmid: 12540832
references.citation: EMBO J. 1993 Sep;12(9):3365-72
references.pmid: 8253064
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5840-6
references.pmid: 16115924
references.citation: Trends Neurosci. 1990 Jul;13(7):266-71
references.pmid: 1695401
references.citation: Proc Natl Acad Sci U S A. 2003 May 13;100(10):6169-73
references.pmid: 12721372
references.citation: J Neurosci. 2002 Jul 1;22(13):5287-90
references.pmid: 12097479
references.citation: Brain Res Brain Res Rev. 1995 Jan;20(1):91-127
references.pmid: 7711769
references.citation: Neuroscience. 1980;5(3):461-514
references.pmid: 6154905
references.citation: J Neurosci. 2000 Mar 15;20(6):2418-26
references.pmid: 10704516
references.citation: J Neurosci. 2005 Aug 24;25(34):7743-53
references.pmid: 16120775
references.citation: Neuron. 2007 Apr 19;54(2):205-18
references.pmid: 17442243
references.citation: Cell. 1998 Oct 2;95(1):17-27
references.pmid: 9778244
references.citation: J Biol Chem. 1994 Aug 12;269(32):20213-6
references.pmid: 8051110
references.citation: Neuron. 2004 May 27;42(4):553-66
references.pmid: 15157418
references.citation: Nature. 1989 Jun 1;339(6223):394-7
references.pmid: 2498664